In investigations involving other tumor types, it has been observed that transformed neuroendocrine carcinomas often emerge in lung adenocarcinomas treated with anti-EGFR therapy and prostate adenocarcinomas subjected to androgen deprivation therapy. This evidence concerns the gene EGFR and lung adenocarcinoma.